Category: SCIENCE & TECHNNOLOGY
HHS Cancels $12 Billion in COVID-19 Pandemic Federal Grants
The U.S. Department of Health and Human Services (HHS) announced on Wednesday that it has canceled approximately $12 billion in federal grants allocated to states during the COVID-19 pandemic. Both federal and state officials confirmed the decision, which impacts funding that had been designated for pandemic response efforts. The cancellation of these grants has raised
Nvidia CEO: New Energy-Efficient Chip Tech Not Ready for GPUs
Nvidia CEO Jensen Huang said Tuesday that a promising new chip technology designed to reduce energy consumption is not yet reliable enough for use in the company’s flagship graphics processing units (GPUs). While the technology holds potential for future advancements, Huang emphasized that it still requires further development before being integrated into Nvidia’s high-performance products.
Pharma Companies Urge US and EU to Exempt Medical Goods from Tariff Wars
Major drugmakers are pressing the Trump administration and European Union officials to exclude medical goods from the escalating tariff wars. The industry fears that tariffs could lead to price hikes on top-selling medicines, including Novo Nordisk’s weight-loss drug Wegovy and Merck’s cancer immunotherapy Keytruda. Pharmaceutical firms argue that imposing tariffs on essential medicines could increase
China’s AgiBot Developing Humanoid Robots for Everyday Tasks
Chinese robotics firm AgiBot is working on humanoid robots designed to perform everyday tasks, including household chores and retail work. The initiative is part of a broader effort to integrate artificial intelligence into daily life, reflecting China’s growing focus on robotics and automation. As AI-driven robots become more advanced, AgiBot aims to revolutionize industries by
Pfizer and BioNTech Win Legal Battle Over COVID-19 Vaccine Patents
Pfizer and BioNTech secured a victory in their legal dispute with Moderna over COVID-19 vaccine patents. On March 5, 2025, the U.S. Patent Trial and Appeal Board ruled that two Moderna patents, which Pfizer and BioNTech were accused of infringing, were invalid. The tribunal concluded that existing knowledge, or “prior art,” invalidated Moderna’s claims. While